Tag: Q3FY25
-
Dr. Reddy’s Laboratories Receives EIR from USFDA for Hyderabad API Facility
Dr. Reddy's Laboratories has received the USFDA's Establishment Inspection Report (EIR) for its Hyderabad API facility, signaling regulatory compliance. This comes alongside a strong Q3 FY25 performance, with a rise in net profit and sales, reinforcing the company's position in the global pharmaceutical market.
-
Amber Enterprises India Posts Strong Q3 FY25 Results, Shares Gain 2.46%
Amber Enterprises India posted impressive Q3 FY25 results, reporting a 64.8% YoY revenue growth and a net profit of Rs 35.87 crore. Strong performance in the Consumer Durable and Electronics divisions, along with strategic business expansion, positions the company for sustained growth.